ALS Alert mastheadALS Alert mastheadSpring 2003 - Science. Scope. Speed

ALS Center Web Site
Research
People and Events

In This Issue:

Drug Trinity Shows Unexpected Strength
Jean-Pierre Julien—his “cocktail” does wonders for ALS mice.

From Iceland: A New Way to Decode ALS Genes
In Iceland, a country of roughly 300,000 citizens, ALS is pretty much unknown. If you wanted to find genes tied to that disease, it’s an unlikely spot for a search. But from that country may come, if not the genes themselves, a superior way to track them down.

Getting to the
Heart of It

With ALS, many of the simplest questions remain unanswered. ‘That just won’t do,’ say Center scientists.

One Step Closer to the Bedside
The Basics Bolster Stem Cell Therapy.

Available Issues:

Winter 2001/2002
Fall 2002
Spring 2003
Fall 2003
Spring 2004
Fall 2004
Winter 2005
Spring/Summer 2005
Fall 2005
Winter 2006

About ALS Alert


From the Clinic

photo - Lora Clawson, M.S.N., C.R.N.P.  
Lora Clawson, M.S.N., C.R.N.P.
   

Lora Clawson, M.S.N., C.R.N.P., manages Johns Hopkins’ ALS clinic, including its clinical trials. In this column she answers typical patients’ questions.

Is depression a symptom of ALS? I mean, is it part of the disease?
No one has shown that depression is a result of ALS’s activity in the nervous system. It’s not like Parkinson’s disease, where mood change can be disease-related. Patients are understandably depressed following diagnosis or after progression of the disease requires a lifestyle-altering step, such as getting a PEG tube or using a wheelchair. But in ALS, there’s not as much depression throughout the course of the disease as some would think.

Not to state the obvious, but patients deal so much better with ALS if they’re not depressed. If symptoms of depression continue—change in sleep patterns, loss of appetite, preoccupation with death issues, loss of concentration or sexual desire, mood swings—we typically prescribe antidepressants. We also emphasize the importance of counseling to deal with the effects of ALS on patients and families.

It takes about six weeks for the drugs to become therapeutic, so we’re in touch with patients weekly during that period, alert for side effects and watching how things are going in general. Fortunately, several of the drugs have added benefit in enhancing sleep and/or decreasing the excess saliva that often occurs in the disease.

What if I still have trouble sleeping?
Sleep may be disturbed for reasons other than depression. Low oxygen levels, difficulty moving or turning in bed or poor sleep hygiene all contribute. The latter is often overlooked, especially in people newly sedentary: too much caffeine, a too-heavy meal, emotional upset before bed, an overstimulating video.

Then what should I do?
Don’t suffer in silence. Talk with your clinic practitioner to get a proper evaluation and appropriate help. Sometimes a small tactic can make a major difference.

If a patient isn’t sleeping, chances are the caregiver isn’t sleeping either, or, at least, is losing essential REM sleep. That contributes to short temper, partner burnout and inability to provide necessary support. So it’s important for caregivers to schedule regular weekly breaks early in the disease—four to eight hours of private time.

Establishing the break early on, so it’s routine, lessens the emotional dependency that can come later in the illness when patients rely completely on caregivers. It can lessen anxiety and feelings of being burdensome that patients may develop. Also, it makes it less likely for caregivers to feel they’re abandoning their loved one if they take time out. Finally, such breaks give patients a chance to see other friends and family members.

Next > A Friend Indeed
Ride for Life Keeps Center Rolling.


Sign up for ALS news, the print version of the newsletter and more:
   
Special Features:

Vantage Point
With approaches to ALS therapy, progress seems to move one step forward and a half step back.

On Center
Runners, Walkers Make Feet Fly to Help the Center.

Rich Soil for a Blooming Friendship
“About six years ago, I ran into Laura and I could tell something wasn’t right,” says Coleman, who now directs the New York State Trial Lawyers Association. “When I heard later she had ALS, I felt a bit strange in writing a personal letter out of the blue, but I sent it anyway.”

Insider's View
Noah Lechtzin, M.D., is a Hopkins pulmonologist who sees ALS clinic patients regularly.

From the Clinic
Lora Clawson, M.S.N., C.R.N.P., manages Johns Hopkins’ ALS clinic, including its clinical trials. In this column she answers typical patients’ questions.

A Friend Indeed
Ride for Life Keeps Center Rolling.

Make a Donation



© Copyright 2003 | All Rights Reserved | Robert Packard Center for ALS Research at Johns Hopkins
600 N. Wolfe Street, Meyer 6-109, Baltimore, Maryland 21287-5953 USA
Site Index Frequently Asked Questions Contact Us Hopkins Medicine